Growth Metrics

Anaptysbio (ANAB) Free Cash Flow (2016 - 2025)

Anaptysbio filings provide 10 years of Free Cash Flow readings, the most recent being $98.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 246.4% year-over-year to $98.0 million, compared with a TTM value of $19.6 million through Dec 2025, up 114.45%, and an annual FY2025 reading of $19.6 million, up 114.45% over the prior year.
  • Free Cash Flow hit $98.0 million in Q4 2025 for Anaptysbio, up from -$27.4 million in the prior quarter.
  • The five-year high for Free Cash Flow was $98.0 million in Q4 2025, with the low at -$66.9 million in Q4 2024.
  • Median Free Cash Flow over the past 5 years was -$23.7 million (2021), compared with a mean of -$17.9 million.
  • The sharpest move saw Free Cash Flow crashed 384.9% in 2022, then skyrocketed 246.4% in 2025.
  • Year by year, Free Cash Flow stood at -$25.3 million in 2021, then surged by 57.91% to -$10.7 million in 2022, then crashed by 219.8% to -$34.1 million in 2023, then plummeted by 96.42% to -$66.9 million in 2024, then soared by 246.4% to $98.0 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $98.0 million, -$27.4 million, and -$40.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.